Kineta (Reverse Merger With Yumanity Therapeutics)
Boston
About Kineta (Reverse Merger With Yumanity Therapeutics)
Yumanity Therapeutics is transforming drug discovery for neurodegenerative diseases caused by protein misfolding. Founded in December 2014 by award-winning protein folding expert, Susan Lindquist, and renowned biotech industry leader, Tony Coles, Yumanity is working to identify and develop new, disease-modifying therapies that address several illnesses with critical unmet medical needs. The initial focus of the company is neurodegenerative diseases, including Alzheimer’s disease, Parkinson’s disease, and amyotrophic lateral sclerosis (ALS). The company’s proprietary platforms have already identified one potential new target for treating Parkinson’s disease, and Yumanity is actively advancing its new chemical lead series for this condition, as well as identifying additional compounds for Alzheimer’s disease and ALS.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Delisted
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $137.4M
- Funding stage: M&A
- Last round: Series Unknown (Dec 2020)
- Ticker: nasdaq:YMTX
- Website: yumanity.com
- Phone: (973) 271-6085
Industries & Categories
Biotechnology, Health Care, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/kineta-reverse-merger-with-yumanity-therapeutics-78467 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.